Sohail S, Alam SN. Breast cancer in pakistan-awareness and early detection 2007.
Taylor RBH. Composition for and method of preventing or treating breast cancer US6300367. (2001).
Kelly GE. Dietary supplements comprising soy hypocotyls containing at least one isoflavone US6497906. (2002).
Lyden D, Hoshino A, Matei I. Organtropic metastatic secretomes and exosomes in breast cancer. Joan and Sanford I Weill Medical College of Cornell University, New York, United States 2016.
Kaufmann JH. Genes differentially expressed in breast cancer US20130196314. (2013).
Raghu K. Basement membranes: Structure, assembly and role in tumor angiogenesis. Nat Med 2003; 3: 442-33.
Xian W. Isolation of non-embryonic stem cells and uses thereof US20190194608. (2019).
Kefalides N, Alper R. Structure and organization of macromolecules in basement membranes Collagen. CRC Press: Boca Raton, FL, USA 2018; pp. 73-94.
Tsiper MV. Tumor encapsulation for prevention and treatment of metastatic cancer disease US8377484. (2013).
Hamilton GAW. Devices, systems and methods for inhibiting invasion and metastases of cancer US20170285003. (2017).
Sanofi Aventis Germany GmbH Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction EP1070727. (2001).
Willumsen NB. Nidogen-1 fragments assay US20190257837. (2019).
Chiang M-D, Kenneth W. Modulation of nidogen expression US20040097451 2004.
Lyden DCH. Methods and reagents for determination and treatment of organotropic metastasis US20190049435. (2019).
Hole SJWOR, Richard D. Methods of profiling gene expression, protein or metabolite levels US20040157229. (2004).
Doudna JAJ. Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription US10421980. (2019).
Potti AN, Joseph R. Predicting responsiveness to cancer therapeutics US20100279957. (2010).
Giancotti FG. Gene expression profiles associated with metastatic breast cancer US20150184247. (2015).
Bonnet SR. Method of in-vitro immunoassay US20130017537. (2013).
El-Helali AM. Gene signatures for cancer detection and treatment US20190127805. (2019).
Massague JZ. Gene Signatures for the prognosis of cancer US20110053804. (2011).
Krause AL. Cancer detection method US20090269744. (2009).
Massague JG, Gaorav P. Method of predicting and reducing risk of metastasis of breast cancer to lung US20080213258. (2008).
Piccolo SC. Prognosis of breast cancer patients by monitoring the expression of two genes US20150322533. (2015).
Skog JKOB, Xandra O, Dennis B. Use of microvesicles in diagnosis and prognosis of medical diseases and conditions US20110003704. (2011).
Keely PJP, Paolo P. Stromal collagen in the diagnosis and characterization of breast cancer US7805183. (2010).
Di Vizio DF, Michael R. Methods for detecting and treating cancer metastasis US10254285. (2019).
Plasslick-Deetjen JB. Method and kit for diagnosing Epithelial-to- Mesenchymal Transition (EMT) of the peritoneum US20180246098. (2018).
Lawman MJPL. Materials and methods for treating oncological disease US7094603. (2006).
Lawman MJPL, Patricia D. Multi-indication mRNA cancer immunotherapy US9636388. (2017).
Lawman MJPL. Tumor cell vaccines US7795020. (2010).
Reinhardt CS. Treatment of metastatic breast cancer US20090304716. (2009).
Poola I. Methods for determining breast cancer risk US20190361027. (2019).